Treatment of Obsessive-Compulsive Disorder

NCT ID: NCT00000373

Last Updated: 2013-11-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 74 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1992-09-30
• Study Completion Date: 2003-07-31

Brief Summary

The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics).

There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.

Detailed Description

To advance the neurobiology and treatment of obsessive-compulsive disorder (OCD) by focusing on Tourette's Syndrome (TS)-spectrum OCD as a possible homogeneous form of OCD, and investigating the relevance of intact 5-hydroxytryptamine (5-HT) function to the mechanism of anti-OC drug action. The validity of TS-spectrum OCD as a distinct subtype is assessed using a detailed clinical, family, drug treatment response profile in adult OCD patients.

In Study I, patients are divided prospectively into 2 putative subtypes (TS-spectrum and non-TS-spectrum OCD) on the basis of clinical history and direct, structured interviews of family members (approximately 400 interviews).

In Study II, patients enter an 8-week single-blind trial with the potent and selective 5-HT reuptake inhibitor fluoxetine (FX). Patients with an incomplete response to FX alone (approximately 64 patients) are randomized to a 4-week double-blind trial of FX in combination with the dopamine (DA) 2 antagonist olanzapine (OLA) or placebo (PLA).

Conditions

Obsessive-Compulsive Disorder

Keywords

Adolescence; Adult; Antipsychotic Agents; Dopamine Antagonists; Female; Fluvoxamine; Haloperidol; Human; Male; Middle Age; Obsessive-Compulsive Disorder; Placebos; Serotonin Uptake Inhibitors; Tourette Syndrome; Tryptophan; Drug Combinations; Antipsychotic Agents -- *therapeutic use; Fluvoxamine -- *therapeutic use; Haloperidol -- *therapeutic use; Obsessive-Compulsive Disorder -- *drug therapy; Obsessive-Compulsive Disorder -- physiopathology; Serotonin Uptake Inhibitors -- *therapeutic use

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

olanzapine + fluoxetine

The specific aim was to determine whether combined treatment with fluoxetine plus olanzapine would be more effective than fluoxetine plus placebo in treating OCD subjects who were partial or nonresponders to a prospective, 8-week, open-label trial of fluoxetine.

Group Type: ACTIVE_COMPARATOR

placebo + fluoxetine

Intervention Type: DRUG

placebo + fluoxetine

The specific aim was to determine whether combined treatment with fluoxetine plus olanzapine would be more effective than fluoxetine plus placebo in treating OCD subjects who were partial or nonresponders to a prospective, 8-week, open-label trial of fluoxetine.

Group Type: PLACEBO_COMPARATOR

olanzapine + fluoxetine

Intervention Type: DRUG

Interventions

olanzapine + fluoxetine

Intervention Type: DRUG

placebo + fluoxetine

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Inclusion criteria required that subjects, ages 14-70 years, have at least a 1-year duration of a current Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) principal diagnosis of OCD. Furthermore, the OCD had to be defined by a rating of "moderate" or greater on the global severity item of the Clinical Global Impressions (CGI) scale and have a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of 19 or greater.

Exclusion criteria included primary depression, schizophrenia, or other psychotic disorders; active bipolar disorder; abuse of alcohol or other significant substance within 6 months; increased risk of seizures or history of neurosurgery, encephalitis, or significant head trauma; or a significant medical condition, such as heart, liver, or renal disease. Subjects with an intelligence quotient of less than 80 as determined with the Kaufman Brief Intelligence Test (Kaufman and Kaufman 1990) were excluded.

• Minimum Eligible Age: 14 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Mental Health (NIMH)

NIH

Sponsor Role: collaborator

University of Florida

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Wayne Goodman, MD

Role: PRINCIPAL_INVESTIGATOR

University of Florida

Locations

Psychiatric Specialty Clinic, Shands Hospital at the University of Florida

Gainesville, Florida, United States

University of Florida Behavioral Health Mandarin Clinic

Jacksonville, Florida, United States

Countries

United States

References

Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P, Goodman WK. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry. 2004 Mar 1;55(5):553-5. doi: 10.1016/j.biopsych.2003.11.010.

Reference Type: BACKGROUND

PMID: 15023585 (View on PubMed)

Koran LM, Bromberg D, Hornfeldt CS, Shepski JC, Wang S, Hollander E. Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder. Compr Psychiatry. 2010 Jul-Aug;51(4):373-9. doi: 10.1016/j.comppsych.2009.10.001. Epub 2009 Dec 21.

Reference Type: DERIVED

PMID: 20579510 (View on PubMed)

Other Identifiers

R01MH045802

Identifier Type: NIH

Identifier Source: secondary_id

View Link

R01MH045802

Identifier Type: NIH

Identifier Source: org_study_id

View Link